The global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, which are highly sought after as treatments for type 2 diabetes and obesity, is increasing. This deficit is attributed to the unexpected increase in demand for GLP-1 receptor agonists. This has caused significant harm to...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV disease or with multiple risk factors. In addition, ...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
Obesity has become a global public health issue, with the number of overweight/obese individuals increasing annually. However, weight loss faces various difficulties and challenges. Incretin medications, represented by glucagon-like peptide-1 (GLP-1), have brought new hope in the battle against obesi...
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that pla...
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incret... JR Unger,CG Parkin - 《Diabetes Therapy》 被...
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that promotes healthy insulin signaling, regulates blood sugar levels, and suppresses appetite. Consequently, numerous GLP-1 receptor (GLP-1R) stimulating drugs have been developed and approved by the US Food and Drug Administration (FDA) ...
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
Glucagon-like peptide 1 (GLP-1) agonists are medications approved for treatment of diabetes that recently have also been used off label for weight loss.1Studies have found increased risks of gastrointestinal adverse events (biliary disease,2pancreatitis,3bowel obstruction,4and gastroparesis5) in patie...
Glucagon-like peptide (GLP)-1 receptor agonists have revolutionized the treatment of patients withtype 2 diabetes mellitusand obesity. These medications stimulate glucose-dependentinsulin releasefrom the pancreas, slow gastric emptying, and inhibit postmealglucagon release, which lead to...